Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients.

Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients.

Bibliographic Details
Main Authors:	Calne, R, Friend, P, Moffatt, S, Bradley, A, Hale, G, Firth, J, Bradley, J, Smith, K, Waldmann, H
Format:	Journal article
Language:	English
Published:	1998

Similar Items

Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients.
by: Calne, R, et al.
Published: (1999)

Reversal of allograft rejection using the monoclonal antibody, Campath-1G.
by: Friend, P, et al.
Published: (1991)

Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up.
by: Watson, C, et al.
Published: (2004)

Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
by: Clatworthy, MR, et al.
Published: (2009)

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
by: Watson, C, et al.
Published: (2005)

Delayed allograft rejection in primates treated with anti-IL-2 receptor monoclonal antibody Campath-6.
by: Tighe, H, et al.
Published: (1988)

Pilot study of CAMPATH-1, a rat monoclonal antibody that fixes human complement, as an immunosuppressant in organ transplantation.
by: Hale, G, et al.
Published: (1986)

CAMPATH-1 FOLLOWING RENAL-TRANSPLANTATION - A RANDOMIZED TRIAL
by: Friend, P, et al.
Published: (1988)

CAMPATH-1H for the treatment of acute rejection in kidney transplant recipients: 10 year follow-up
by: Clatworthy, MR, et al.
Published: (2007)

Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies.
by: Naparstek, E, et al.
Published: (1999)

Campath-1M--prophylactic use after kidney transplantation. A randomized controlled clinical trial.
by: Friend, P, et al.
Published: (1989)

CAMPATH: from concept to clinic.
by: Waldmann, H, et al.
Published: (2005)

The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients
by: Eng, H.S., et al.
Published: (2006)

T-cell depletion of stem cell grafts with campath-1H "in the bag" followed by cyclosporin immunosuppression remains a cost effective strategy in transplantation
by: Novitzky, N, et al.
Published: (2004)

Specificity of monoclonal antibody Campath-1.
by: Hale, G, et al.
Published: (1988)

CAMPATH-1H in inflammatory arthritis.
by: Watts, R, et al.
Published: (1993)

Availability of Campath-1 antibodies for bone marrow transplantation.
by: Hale, G, et al.
Published: (1995)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
by: Hale, G, et al.
Published: (1994)

Addition of cyclosporin post transplantation decreases GvHD without enhancing the adverse effect of T-cell depletion with CAMPATH-1H "in the bag": The cape town experience
by: Novitzky, N, et al.
Published: (2003)

Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection.
by: Rebello, P, et al.
Published: (1999)

The CAMPATH-1 antigen (CDw52).
by: Hale, G, et al.
Published: (1990)

Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
by: Hale, G, et al.
Published: (1994)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
by: Hale, G, et al.
Published: (1988)

CAMPATH-IH in multiple sclerosis.
by: Moreau, T, et al.
Published: (1996)

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
by: Hale, G, et al.
Published: (1996)

Leukaemic relapse after Campath 1-treated bone-marrow transplantation for leukaemia.
by: Waldmann, H, et al.
Published: (1987)

Campath-1H therapy in refractory ocular inflammatory disease.
by: Dick, A, et al.
Published: (2000)

Determination of Criteria and Drought Tolerance of Prope-Legitimate Cocoa Seed Through Polyethylene Glycol Induction
by: Maera Zasari, et al.
Published: (2020-08-01)

TREATMENT OF RHEUMATOID-ARTHRITIS WITH HUMANIZED ANTILYMPHOCYTE ANTIBODY CAMPATH-1H
by: Watts, R, et al.
Published: (1992)

Islet allografting in the dog model: potential therapies for tolerance induction.
by: Brons, I, et al.
Published: (1995)

Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
by: Williams, R, et al.
Published: (2000)

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
by: Hale, G, et al.
Published: (2002)

CAMPATH-1 MOAB IN THE TREATMENT OF REFRACTORY AUTOIMMUNE THROMBOCYTOPENIC PURPURA (ATP)
by: Lim, S, et al.
Published: (1993)

Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience.
by: Novitzky, N, et al.
Published: (2004)

Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H.
by: Isaacs, J, et al.
Published: (1996)

Sustained remission of severe resistant autoimmune neutropenia with Campath-1H.
by: Killick, S, et al.
Published: (1997)

CAMPATH-1 antibodies in stem-cell transplantation.
by: Hale, G, et al.
Published: (2001)

Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen.
by: Xia, M, et al.
Published: (1993)

Immunosuppression of canine renal allograft recipients by CD4 and CD8 monoclonal antibodies.
by: Watson, C, et al.
Published: (1994)

Rat monoclonal antibodies for bone marrow transplantation--the CAMPATH series.
by: Waldmann, H, et al.
Published: (1985)